8.94
-0.08(-0.89%)
Currency In USD
| Previous Close | 9.02 |
| Open | 9.02 |
| Day High | 9.05 |
| Day Low | 8.86 |
| 52-Week High | 11.31 |
| 52-Week Low | 6.02 |
| Volume | 1.41M |
| Average Volume | 4.74M |
| Market Cap | 1.87B |
| PE | -34.38 |
| EPS | -0.26 |
| Moving Average 50 Days | 9.96 |
| Moving Average 200 Days | 8.3 |
| Change | -0.08 |
If you invested $1000 in BioCryst Pharmaceuticals, Inc. (BCRX) 10 years ago, it would be worth $590.49 as of July 04, 2025 at a share price of $8.94. Whereas If you bought $1000 worth of BioCryst Pharmaceuticals, Inc. (BCRX) shares 5 years ago, it would be worth $1,806.06 as of July 04, 2025 at a share price of $8.94.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million
GlobeNewswire Inc.
Jun 27, 2025 11:00 AM GMT
—Neopharmed Gentili will pay BioCryst $250 million upfront for the European assets and rights related to ORLADEYO, and up to $14 million in future milestones— —BioCryst plans to use proceeds to retire all remaining term debt, which will eliminate app
BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI
GlobeNewswire Inc.
Jun 16, 2025 11:00 AM GMT
—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile— —Patients report improved quality of life and daily functioning with ORLADEYO— RESEARCH TRIANGLE PARK, N.C., June
ORLADEYO® (berotralstat) Approved in Colombia
GlobeNewswire Inc.
Jun 13, 2025 11:00 AM GMT
RESEARCH TRIANGLE PARK, N.C., June 13, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Institute of Drug and Food Surveillance (INVIMA) in Colombia has granted approval for oral, once-daily O